WALTHAM, Mass., July 20 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) announced today that it has entered into an
agreement with Chesapeake Biological Laboratories, Inc. (Nasdaq: CBLI) for the
latter to provide manufacturing services for ImmuLogic's cocaine and nicotine
vaccine products. Dr. Joseph Marr, President and C.E.O. of ImmuLogic, said,
"We are very pleased to have entered into this agreement with Chesapeake
Biological Laboratories (CBL). This relationship provides ImmuLogic with a
reliable source for both developmental and commercial quantities of our
cocaine and nicotine vaccine products. CBL is an organization with a strong
reputation for quality and timely performance. This arrangement will permit
ImmuLogic to focus on its research and development activities, confident that
our manufacturing needs are well served."
John C. Weiss, III, President of CBL, stated, "We are delighted to be part
of a manufacturing process that will aid so many people afflicted with drug
dependencies. Weiss further added, "These vaccines will be initially produced
at our Experimental Products Division at the Seton Business Park and will
eventually be transferred to our new 71,000 square foot commercial production
facility in the Camden Industrial Park in downtown Baltimore."
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, MA, focused on the development of vaccines for substance
abuse. The Company's press releases are available through Company News On
Call by fax at 800-758-5804, ext. 114501, and on the Internet at
http://www.prnewswire.com.
This press release contains forward-looking statements that involve a
number of risks and uncertainties. Among the most important factors that
could cause actual results to differ materially from those indicated by such
forward-looking statements are delays in product development, failure to
obtain required regulatory approvals, and the risk factors detailed in the
Company's 10-K for the year ended December 31, 1997.
SOURCE ImmuLogic Pharmaceutical Corporation
 back to top
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 114501
CONTACT:
Investor Relations, ImmuLogic Pharmaceutical
Corporation, 781-466-6000
|
